Список литературы к Главе 10

31. Hamblin T.J. et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia // Blood. 1999. Vol. 94, N 6. P. 1848–1854.

32. Rossi D. et al. Molecular prediction of durable remission after first­line fludarabine­cyclophosphamide­rituximab in chronic lymphocytic leukemia // Blood. 2015. Vol. 126, N 16. P. 1921–1924.

33. Fischer K. et al. Long­term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial // Blood. 2016. Vol. 127, N 2. P. 208–215.

34. Thompson P.A. et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long­term disease­free survival in IGHV­mutated chronic lymphocytic leukemia // Blood. 2016. Vol. 127, N 3. P. 303–309.

35. Stamatopoulos K. et al. Antigen receptor stereotypy in chronic lymphocytic leukemia // Leukemia. 2017. Vol. 31, N 2. P. 282–291.

36. Baliakas P. et al. Not all IGHV3­21 chronic lymphocytic leukemias are equal: prognostic considerations // Blood. 2015. Vol. 125, N 5. P. 856–859.

37. Döhner H. et al. Genomic aberrations and survival in chronic lymphocytic leukemia // N. Engl. J. Med. 2000. Vol. 343, N 26. P. 1910–1916.

38. Pospisilova S. et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia // Leukemia. 2012. Vol. 26, N 7. P. 1458–1461.

39. Grever M.R. et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997 // J. Clin. Oncol. 2007. Vol. 25, N 7. P. 799–804.

40. Stilgenbauer S. et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial // Blood. 2014. Vol. 123, N 21. P. 3247–3254.

41. Zenz T. et al. TP53 mutation and survival in chronic lymphocytic leukemia // J. Clin. Oncol. 2010. Vol. 28, N 29. P. 4473–4479.

42. Shanafelt T.D. et al. Prospective evaluation of clonal evolution during long­term follow­up of patients with untreated early­stage chronic lymphocytic leukemia // J. Clin. Oncol. 2006. Vol. 24, N 28. P. 4634–4641.

43. Buhmann R. et al. CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B­cell chronic lymphocytic leukaemia cells // Br. J. Haematol. 2002. Vol. 118, N 4. P. 968–975.

44. Mayr C. et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia // Blood. 2006. Vol. 107, N 2. P. 742–751.

45. Haferlach C. et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping // Leukemia. 2007. Vol. 21, N 12. P. 2442–2451.

46. Baliakas P. et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact // Blood. 2019. Vol. 133, N 11. P. 1205–1216.

47. Thompson P.A. et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib­based regimens // Cancer. 2015. Vol. 121, N 20. P. 3612–3621.

48. Herling C.D. et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil­based chemotherapy or chemoimmunotherapy // Blood. 2016. Vol. 128, N 3. P. 395–404.

49. Wierda W.G. et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia // Blood. 2007. Vol. 109, N 11. P. 4679–4685.

50. Pflug N. et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia // Blood. 2014. Vol. 124, N 1. P. 49–62.

51. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL­IPI): a meta­analysis of individual patient data // Lancet Oncol. 2016. Vol. 17, N 6. P. 779–790.

52. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia et al. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial // N. Engl. J. Med. 1988. Vol. 319, N 14. P. 902–907.

53. Boughton B.J. et al. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia // Clin. Lab. Haematol. 1995. Vol. 17, N 1. P. 75–80.

54. Molica S. et al. Prophylaxis against infections with low­dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study // Haematologica. 1996. Vol. 81, N 2. P. 121–126.

55. Raanani P. et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta­analysis // Leuk. Lymphoma. 2009. Vol. 50, N 5. P. 764–772.

56. Sklenar I. et al. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma // Oncology. 1993. Vol. 50, N 6. P. 466–477.

57. Kim H.Y., Kim W. Chemotherapy­related reactivation of hepatitis B infection: updates in 2013 // World J. Gastroenterol. 2014. Vol. 20, N 40. P. 14 581–14 588.

58. Yazici O., Sendur M.A., Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies // World J. Gastroenterol. 2014. Vol. 20, N 22. P. 6716–6724.

59. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., Pasternack B.S. Clinical staging of chronic lymphocytic leukemia // Blood. 1975. Vol. 46, N 2. P. 219–234.

60. Binet J.L. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis // Cancer. 1981. Vol. 48, N 1. P. 198–206.

61. Zent C.S. et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma // Br. J. Haematol. 2008. Vol. 141, N 5. P. 615–621.

62. Cramer P., Hallek M. Prognostic factors in chronic lymphocytic leukemia – what do we need to know? // Nat. Rev. Clin. Oncol. 2011. Vol. 8, N 1. P. 38–47.

63. Amaya­Chanaga C.I., Rassenti L.Z. Biomarkers in chronic lymphocytic leukemia: clinical applications and prognostic markers // Best Pract. Res. Clin. Haematol. 2016. Vol. 29, N 1. P. 79–89.

64. Parikh S.A., Shanafelt T.D. Prognostic factors and risk stratification in chronic lymphocytic leukemia // Semin. Oncol. 2016. Vol. 43, N 2. P. 233–240.

65. Gentile M. et al. Validation of the CLL­IPI and comparison with the MDACC prognostic index in newly diagnosed patients // Blood. 2016. Vol. 128, N 16. P. 2093–2095.

66. da Cunha­Bang C. et al. Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo­immunotherapy: a Danish population­based study of 10455 patients // Blood Cancer J. 2016. Vol. 6, N 11. P. e499.

67. da Cunha­Bang C., Christiansen I., Niemann C.U. The CLL­IPI applied in a population­based cohort // Blood. 2016. Vol. 128, N 17. P. 2181–2183.

68. Rigolin G.M. et al. In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL­IPI // Blood. 2017. Vol. 129, N 26. P. 3495–3498.

69. Molica S. et al. Chronic lymphocytic leukemia international prognostic index: a systematic review and meta­analysis // Blood. 2018. Vol. 131, N 3. P. 365–368.

70. Molica S. et al. Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL­international prognostic index (CLL­IPI) // Leuk. Lymphoma. 2017. Vol. 58, N 7. P. 1736–1739.

71. Gentile M. et al. Comparison between the CLL­IPI and the Barcelona­Brno prognostic model: analysis of 1299 newly diagnosed cases // Am. J. Hematol. 2018. Vol. 93, N 2. P. E35–E37.

72. Muntañola A. et al. Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia // J. Clin. Oncol. 2007. Vol. 25, N 12. P. 1576–1580.

73. Gentile M. et al. Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O­CLL1­GISL study // Eur. J. Haematol. 2016. Vol. 96, N 1. P. 36–45.

74. Eichhorst B.F. et al. Limited clinical relevance of imaging techniques in the follow­up of patients with advanced chronic lymphocytic leukemia: results of a meta­analysis // Blood. 2011. Vol. 117, N 6. P. 1817–1821.

75. Bruzzi J.F. et al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT // J. Nucl. Med. 2006. Vol. 47, N 8. P. 1267–1273.

76. Falchi L. et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia // Blood. 2014. Vol. 123, N 18. P. 2783–2790.

77. Michallet A.S. et al. An 18F­FDG­PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter’s syndrome // Leuk. Lymphoma. 2016. Vol. 57, N 6. P. 1474–1477.

78. Mato A.R. et al. Utility of positron emission tomography­computed tomography in patients with chronic lymphocytic leukemia following B­cell receptor pathway inhibitor therapy // Haematologica. 2019. Vol. 104, N 11. P. 2258–2264.

79. Dighiero G. et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia // N. Engl. J. Med. 1998. Vol. 338, N 21. P. 1506–1514.

80. Hoechstetter M.A. et al. Early, risk­adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group // Leukemia. 2017. Vol. 31, N 12. P. 2833–2837.

81. Herling C.D. et al. Early treatment with FCR versus watch and wait in patients with stage Binet A high­risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial // Leukemia. 2020. Vol. 34, N 8. P. 2038–2050.

82. Langerbeins P. et al. The CLL12 trial protocol: a placebo­controlled double­blind phase III study of ibrutinib in the treatment of early­stage chronic lymphocytic leukemia patients with risk of early dis­ ease progression // Future Oncol. 2015. Vol. 11, N 13. P. 1895–1903.

83. Cheson B.D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non­Hodgkin lymphoma: the Lugano classification // J. Clin. Oncol. 2014. Vol. 32, N 27. P. 3059–3068.

84. Kovacs G. et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group // J. Clin. Oncol. 2016. Vol. 34, N 31. P. 3758–3765.

85. Böttcher S., Ritgen M., Dreger P. Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies // Blood Rev. 2011. Vol. 25, N 2. P. 91–96.

86. Rawstron A.C. et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia // Leukemia. 2007. Vol. 21, N 5. P. 956–964.